Home / About CAR T

CAR T-cell therapy for ALL uses the target specificity of antibody therapy to direct the cytotoxic immune response¹

The autologous anti-CD19 CAR T-cell therapy,
TECARTUS^®, is individually prepared from each patient’s
T-cells in a 6-step process²:

The autologous anti-CD19 CAR T-cell
therapy, TECARTUS^®, is individually
prepared from each patient’s
T-cells in a 6-step process²:

Leukapheresis

Obtain peripheral blood mononuclear cells

Selection

Isolate T-cells to reduce the
likelihood that circulating tumor
cells drive the exhaustion of
CAR T-cells

Activation

Activate T-cells using anti-CD3 and
anti-CD28 antibodies + IL-2

Transduction

Insert anti-CD19
CAR transgene

T-cell Expansion

In cell culture, expand the number of
CAR T-cells to achieve dose

Suspension

Formulate CAR T-cells into
suspension for infusion

ALL=acute lymphoblastic leukemia; CAR=chimeric antigen receptor; CD=cluster of differentiation; IL-2=interleukin-2.

References: 1. Feins S, Kong W, Williams EF, Milone MC, Fraietta JA. An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol. 2019;94(S1):S3-S9. 2. TECARTUS^® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2024.

Up next: Design & Manufacturing >

NEW 4-YEAR OS DATA FOR SINGLE-INFUSION CAR T-CELL THERAPY HERE

CAR T-cell therapy for ALL uses the target specificity of antibody therapy to direct the cytotoxic immune response1

CAR T-cell therapy for ALL uses the target specificity of antibody therapy to direct the cytotoxic immune response¹